{"id":"lamotrigine-generic-b","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Rash (including Stevens-Johnson syndrome risk)"},{"rate":"20-30","effect":"Dizziness"},{"rate":"15-25","effect":"Ataxia"},{"rate":"10-20","effect":"Somnolence"},{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Diplopia"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lamotrigine stabilizes neuronal membranes by blocking sodium channels, which prevents repetitive neuronal firing. It also inhibits the release of glutamate, an excitatory neurotransmitter, thereby reducing excessive neuronal activity. These combined effects make it effective as an anticonvulsant and mood stabilizer.","oneSentence":"Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:36.764Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (adjunctive therapy for partial seizures)"},{"name":"Bipolar I disorder (maintenance treatment to delay time to occurrence of mood episodes)"}]},"trialDetails":[{"nctId":"NCT01733394","phase":"PHASE4","title":"Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study)","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2012-12-12","conditions":"Epilepsy","enrollment":54},{"nctId":"NCT01713777","phase":"PHASE4","title":"Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2013-04","conditions":"Epilepsy","enrollment":35}],"_emaApprovals":[],"_faersSignals":[{"count":250952,"reaction":"DRUG INEFFECTIVE"},{"count":189456,"reaction":"OFF LABEL USE"},{"count":188664,"reaction":"FATIGUE"},{"count":186509,"reaction":"NAUSEA"},{"count":161270,"reaction":"DIARRHOEA"},{"count":146998,"reaction":"DYSPNOEA"},{"count":137300,"reaction":"PAIN"},{"count":136932,"reaction":"HEADACHE"},{"count":122125,"reaction":"VOMITING"},{"count":120258,"reaction":"DIZZINESS"}],"_approvalHistory":[{"date":"20250821","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20170106","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20101223","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20250821","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20250821","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20250821","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20250821","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20250821","type":"SUPPL","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20091014","type":"ORIG","sponsor":"STRIDES PHARMA","applicationNumber":"ANDA078418"},{"date":"20230829","type":"ORIG","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA212634"},{"date":"20240813","type":"SUPPL","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA212634"},{"date":"20240501","type":"SUPPL","sponsor":"STRIDES PHARMA INTL","applicationNumber":"ANDA212634"},{"date":"20200915","type":"ORIG","sponsor":"AVET","applicationNumber":"ANDA205360"},{"date":"20240726","type":"SUPPL","sponsor":"AVET LIFESCIENCES","applicationNumber":"ANDA202693"},{"date":"20240726","type":"SUPPL","sponsor":"AVET LIFESCIENCES","applicationNumber":"ANDA202693"},{"date":"20141219","type":"ORIG","sponsor":"AVET LIFESCIENCES","applicationNumber":"ANDA202693"}],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lamotrigine generic \"B\"","genericName":"Lamotrigine generic \"B\"","companyName":"University of Cincinnati","companyId":"university-of-cincinnati","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability. Used for Epilepsy (adjunctive therapy for partial seizures), Bipolar I disorder (maintenance treatment to delay time to occurrence of mood episodes).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}